>
Switch to:

Calliditas Therapeutics AB EV-to-Revenue

: 6,020.19 (As of Today)
View and export this data going back to 2020. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Calliditas Therapeutics AB's enterprise value is $577.83 Mil. Calliditas Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was $0.10 Mil. Therefore, Calliditas Therapeutics AB's EV-to-Revenue for today is 6,020.19.

NAS:CALT' s EV-to-Revenue Range Over the Past 10 Years
Min: 8.64   Med: 38.52   Max: 7184.29
Current: 5506.59

8.64
7184.29

During the past 6 years, the highest EV-to-Revenue of Calliditas Therapeutics AB was 7184.29. The lowest was 8.64. And the median was 38.52.

NAS:CALT's EV-to-Revenue is ranked lower than
99% of the 1005 Companies
in the Drug Manufacturers industry.

( Industry Median: 3.54 vs. NAS:CALT: 5506.59 )

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2021-05-16), Calliditas Therapeutics AB's stock price is $27.71. Calliditas Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was $0.00. Therefore, Calliditas Therapeutics AB's PS Ratio for today is 9,236.67.


Calliditas Therapeutics AB EV-to-Revenue Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
EV-to-Revenue Premium Member Only - - - 11.81 6,889.42

Calliditas Therapeutics AB Quarterly Data
Dec15 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.81 13.74 83.89 83.23 6,889.42

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Calliditas Therapeutics AB EV-to-Revenue Distribution

* The bar in red indicates where Calliditas Therapeutics AB's EV-to-Revenue falls into.



Calliditas Therapeutics AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Calliditas Therapeutics AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=577.829/0.095981779798125
=6,020.19

Calliditas Therapeutics AB's current Enterprise Value is $577.83 Mil.
Calliditas Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2020 was 0.048152625537146 (Mar. 2020 ) + 0 (Jun. 2020 ) + 0 (Sep. 2020 ) + 0.04782915426098 (Dec. 2020 ) = $0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB  (NAS:CALT) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Calliditas Therapeutics AB's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=27.71/0.003
=9,236.67

Calliditas Therapeutics AB's share price for today is $27.71.
Calliditas Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2020 was 0.001 (Mar. 2020 ) + 0 (Jun. 2020 ) + 0 (Sep. 2020 ) + 0.002 (Dec. 2020 ) = $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Calliditas Therapeutics AB EV-to-Revenue Related Terms


Calliditas Therapeutics AB EV-to-Revenue Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)